SCHEMBL2312401

SCHEMBL2312401

CCCCCCOc1ccc(C(=O)OCC)cc1O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.59
CA1 P00915 1/20 0.59
CA2 P00918 1/20 0.59
CA7 P43166 1/20 0.59
CA9 Q16790 1/20 0.59
CA14 Q9ULX7 1/20 0.59
ESR1 P03372 3/20 0.57
AKR1C4 P17516 1/20 0.57
AKR1C3 P42330 1/20 0.57
AKR1C2 P52895 1/20 0.57
AKR1C1 Q04828 1/20 0.57
HSD17B2 P37059 1/20 0.54
SMPD1 P17405 1/20 0.53
HDAC6 Q9UBN7 1/20 0.51
ALDH1A1 P00352 2/20 0.50
CNR2 P34972 2/20 0.50
NPC1 O15118 1/20 0.50
MAPT P10636 1/20 0.50
RAB9A P51151 1/20 0.50
HPGD P15428 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27734000 1.00 CA12 (0.59) CA12CA1CA2CA7CA9
SCHEMBL11340705 1.00 CA12 (0.59) CA12CA1CA2CA7CA9
SCHEMBL13529206 0.99 CA12 (0.60) CA12CA1CA2CA7CA9
SCHEMBL8071707 0.94 CA12 (0.62) CA12CA1CA2CA7CA9
SCHEMBL13529205 0.90 CA12 (0.64) CA12CA1CA2CA7CA9
SCHEMBL1201551 0.89 SMPD1 (0.58) ESR1HSD17B2SMPD1ALDH1A1NPC1
SCHEMBL4328843 0.88 CA12 (0.55) CA12CA1CA2CA7CA9
SCHEMBL9699845 0.87 SMPD1 (0.58) CA12CA1CA2CA7CA9
SCHEMBL1199891 0.87 SMPD1 (0.56) CA12CA1CA2CA7CA9
SCHEMBL13693079 0.87 ESR1 (0.65) ESR1AKR1C4AKR1C3AKR1C2AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1846366-B1 NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2011-08-03 EP disclosed
US-7718703-B2 Norvaline derivative and method for preparation thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-05-18 US disclosed
US-20080076769-A1 Norvaline Derivative and Method for Preparation Thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-03-27 US disclosed
EP-1846366-A1 NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF TANABE SEIYAKU CO., LTD. (JP) 2007-10-24 EP disclosed
WO-2006080477-A1 NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF TANABE SEIYAKU CO., LTD. (JP) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076769-A1 Norvaline Derivative and Method for Preparation Thereof SLC38A7, SLC7A1, SLC6A7 CA12 4250/4885CA1 4040/4885CA2 2087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.